[Use of long-acting L-asparaginase (PEG-asparaginase) in acute lymphoblastic leukemia].
Twenty-five patients with acute lymphoblastic leukemia [15 adults and 10 children] received standard treatment in which regular L-asparaginase was replaced for L-asparaginase of prolonged action [PEG-asparaginase]. The drug was administered once in two weeks in a dose 2500 IU/m2 for remission induction and consolidation or as a component of maintenance therapy. It was found that the response to primary PEG-asparaginase treatment or its use in the disease relapses produced the same response as regular L-asparaginase, being superior in convenience and feasibility of outpatient use. Side effects in the form of hypoproteinemia, hepatic toxicity and toxic pancreatitis [in children, 9 and 1 adults, respectively] were moderate and disappeared after 10-20-day discontinuation of the drug.
Volkova
M A
MA
Maiakova
S A
SA
Kaletin
G I
GI
Kurdiukov
B V
BV
Frenkel'
M A
MA
Protasova
A K
AK
Tupitsyn
N N
NN
Fleĭshman
E V
EV
D000293:Adolescent; D000328:Adult; D001215:Asparaginase / Q000008:administration & dosage*; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*
D003692:Delayed-Action Preparations; D001215:Asparaginase
Primenenie L-asparaginazy prolongirovannogo deĭstviia (PEG-asparaginazy) pri ostrom limfoblastnom leĭkoze.